Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6F3I

IRAK4 IN COMPLEX WITH inhibitor

6F3I の概要
エントリーDOI10.2210/pdb6f3i/pdb
分子名称Interleukin-1 receptor-associated kinase 4, (3~{R})-3-[4-[[4-(4-ethanoylpiperazin-1-yl)cyclohexyl]amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]butanamide, SULFATE ION, ... (4 entities in total)
機能のキーワードirak4, kinase, inhibitor, cancer, signaling protein
由来する生物種Homo sapiens (Human)
細胞内の位置Cytoplasm : Q9NWZ3
タンパク質・核酸の鎖数2
化学式量合計74007.31
構造登録者
Xue, Y.,Degorce, S.L.,Robb, G.R.,Ferguson, A.D. (登録日: 2017-11-28, 公開日: 2018-05-23, 最終更新日: 2024-11-13)
主引用文献Degorce, S.L.,Anjum, R.,Dillman, K.S.,Drew, L.,Groombridge, S.D.,Halsall, C.T.,Lenz, E.M.,Lindsay, N.A.,Mayo, M.F.,Pink, J.H.,Robb, G.R.,Scott, J.S.,Stokes, S.,Xue, Y.
Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4.
Bioorg. Med. Chem., 26:913-924, 2018
Cited by
PubMed Abstract: We have developed a series of orally efficacious IRAK4 inhibitors, based on a scaffold hopping strategy and using rational structure based design. Efforts to tackle low permeability and high efflux in our previously reported pyrrolopyrimidine series (Scott et al., 2017) led to the identification of pyrrolotriazines which contained one less formal hydrogen bond donor and were intrinsically more lipophilic. Further optimisation of substituents on this pyrrolotriazine core culminated with the discovery of 30 as a promising in vivo probe to assess the potential of IRAK4 inhibition for the treatment of MyD88 mutant DLBCL in combination with a BTK inhibitor. When tested in an ABC-DLBCL model with a dual MyD88/CD79 mutation (OCI-LY10), 30 demonstrated tumour regressions in combination with ibrutinib.
PubMed: 29398441
DOI: 10.1016/j.bmc.2018.01.008
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.14 Å)
構造検証レポート
Validation report summary of 6f3i
検証レポート(詳細版)ダウンロードをダウンロード

227561

件を2024-11-20に公開中

PDB statisticsPDBj update infoContact PDBjnumon